220 related articles for article (PubMed ID: 10640512)
1. Pharmacokinetics of the rapid-acting insulin analog, insulin aspart, in rats, dogs, and pigs, and pharmacodynamics of insulin aspart in pigs.
Plum A; Agerso H; Andersen L
Drug Metab Dispos; 2000 Feb; 28(2):155-60. PubMed ID: 10640512
[TBL] [Abstract][Full Text] [Related]
2. A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study.
Thorisdottir RL; Parkner T; Chen JW; Ejskjaer N; Christiansen JS
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):216-21. PubMed ID: 19175369
[TBL] [Abstract][Full Text] [Related]
3. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
Rave K; Heise T; Weyer C; Herrnberger J; Bender R; Hirschberger S; Heinemann L
Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: Oral delivery using pH-responsive nanoparticles vs. subcutaneous injection.
Sonaje K; Lin KJ; Wey SP; Lin CK; Yeh TH; Nguyen HN; Hsu CW; Yen TC; Juang JH; Sung HW
Biomaterials; 2010 Sep; 31(26):6849-58. PubMed ID: 20619787
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and pharmacokinetics of the insulin-mimetic agent vanadyl acetylacetonate in non-diabetic and diabetic rats.
Zhang SQ; Zhong XY; Lu WL; Zheng L; Zhang X; Sun F; Fu GY; Zhang Q
J Inorg Biochem; 2005 May; 99(5):1064-75. PubMed ID: 15833329
[TBL] [Abstract][Full Text] [Related]
6. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.
von Mach MA; Brinkmann C; Hansen T; Weilemann LS; Beyer J
Exp Clin Endocrinol Diabetes; 2002 Nov; 110(8):416-9. PubMed ID: 12518253
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetic and pharmacodynamic studies of human insulin and analogues in chronic diabetic Yucatan minipigs.
Lin S; Chen LL; Chien YW
J Pharmacol Exp Ther; 1998 Aug; 286(2):959-66. PubMed ID: 9694956
[TBL] [Abstract][Full Text] [Related]
8. The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats.
Zhang SQ; Zhong XY; Chen GH; Lu WL; Zhang Q
J Pharm Pharmacol; 2008 Jan; 60(1):99-105. PubMed ID: 18088510
[TBL] [Abstract][Full Text] [Related]
9. Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial.
Perriello G; Pampanelli S; Porcellati F; Avogaro A; Bosi E; Petrella G; Squatrito S; Furneri S; Marra G; Vitali L; Previti M; Cucinotta D
Diabet Med; 2005 May; 22(5):606-11. PubMed ID: 15842516
[TBL] [Abstract][Full Text] [Related]
10. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp.
Heinemann L; Weyer C; Rave K; Stiefelhagen O; Rauhaus M; Heise T
Exp Clin Endocrinol Diabetes; 1997; 105(3):140-4. PubMed ID: 9228509
[TBL] [Abstract][Full Text] [Related]
12. Comparative clinical pharmacology of human insulin (Novo) and porcine insulin in normal subjects.
Ebihara A; Kondo K; Ohashi K; Kosaka K; Kuzuya T; Matsuda A
Diabetes Care; 1983; 6 Suppl 1():17-22. PubMed ID: 6343032
[TBL] [Abstract][Full Text] [Related]
13. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
Jovanovic L; Giammattei J; Acquistapace M; Bornstein K; Sommermann E; Pettitt DJ
Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
[TBL] [Abstract][Full Text] [Related]
14. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
Becker RH; Frick AD; Burger F; Potgieter JH; Scholtz H
Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
[TBL] [Abstract][Full Text] [Related]
15. Clinical strategies for controlling peaks and valleys: type 1 diabetes.
Bolli GB
Int J Clin Pract Suppl; 2002 Jul; (129):65-74. PubMed ID: 12166610
[TBL] [Abstract][Full Text] [Related]
16. State of insulin self-association does not affect its absorption from the pulmonary route.
Hussain A; Ahsan F
Eur J Pharm Sci; 2005 Jun; 25(2-3):289-98. PubMed ID: 15911225
[TBL] [Abstract][Full Text] [Related]
17. Time-action profile of inhaled insulin.
Heinemann L; Traut T; Heise T
Diabet Med; 1997 Jan; 14(1):63-72. PubMed ID: 9017356
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of microneedles for percutaneous absorption of insulin.
Ito Y; Hagiwara E; Saeki A; Sugioka N; Takada K
Eur J Pharm Sci; 2006 Sep; 29(1):82-8. PubMed ID: 16828268
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes.
Porcellati F; Rossetti P; Ricci NB; Pampanelli S; Torlone E; Campos SH; Andreoli AM; Bolli GB; Fanelli CG
Diabetes Care; 2007 May; 30(5):1261-3. PubMed ID: 17303785
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers.
Kaku K; Matsuda M; Urae A; Irie S
Diabetes Res Clin Pract; 2000 Aug; 49(2-3):119-26. PubMed ID: 10963823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
